



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027

Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027

Publication ID:

DEL0818004

Publication Date:

August 03, 2018

Pages:

120

Publisher:

Delveinsight

Region:

Global [1]

\$6,250.00

Publication License Type *

Single User License (PDF), \$6,250.00

Site License (PDF), \$12,500.00

Global License (PDF), \$18,750.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

DelveInsight's 'Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Primary Biliary Cholangitis (PBC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Primary Biliary Cholangitis (PBC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2016-2027

Primary Biliary Cholangitis (PBC) - Disease Understanding and Treatment Algorithm

Primary Biliary Cholangitis (PBC) is a chronic, progressive liver disorder that mostly affects women and usually appears during middle age. PBC leads to inflammation and scarring of the small bile ducts. If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure. PBC is divided into four stages with stage 1 being early disease, where there is no significant scarring, to stage 4, which is defined by cirrhosis.

The DelveInsight Primary Biliary Cholangitis market report gives the thorough understanding of the Primary Biliary Cholangitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Primary Biliary Cholangitis in the US, Europe, and Japan.

Primary Biliary Cholangitis Epidemiology

The Primary Biliary Cholangitis epidemiology division provides the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Gender Specific Prevalence, and Diagnosed and Treatable Prevalence] scenario of Primary Biliary Cholangitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to American Association for the Study of Liver Diseases (AASLD), in 2016, the prevalence of PBC in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 persons. As per one study conducted by Daniel S. Smyk (February 2012), approximately 7-11% of PBC patients are males.

Primary Biliary Cholangitis Drug Chapters

This segment of the Primary Biliary Cholangitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Currently there is no cure for the treatment for PBC, yet medications are available to slow the progression of disease and prevent complications. Only two FDA approved drugs, Ursodeoxycholic acid (UDCA) and Obeticholic acid are available in market to reduce cirrhosis progression. UDCA doesn't cure primary biliary cholangitis, but it improves liver function and reduce liver scarring.

Primary Biliary Cholangitis Market Outlook

The Primary Biliary Cholangitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

There are different potential drug candidates in the clinical trials for the PBC treatment. Upcoming therapies such as Seladelpar (CymaBay Therapeutics), FFP104 (Fast Forward Pharmaceuticals), Etrasimod (Arena Pharmaceuticals), EDP-305 (Enanta Pharmaceuticals) etc. will significantly impact the PBC market during the study period (2016-2027).

Primary Biliary Cholangitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Primary Biliary Cholangitis Report Insights

- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies

Primary Biliary Cholangitis Report Key Strengths

- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake

Primary Biliary Cholangitis Report Assessment

- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers

Key Benefits

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Primary Biliary Cholangitis market
- Organize sales and marketing efforts by identifying the best opportunities for Primary Biliary Cholangitis market
- To understand the future market competition in the Primary Biliary Cholangitis market.

Please Note - This report will available in 7-10 Business Days after purchase.

Table Of Contents:

1. Report Introduction
2. Primary Biliary Cholangitis (PBC) Market Overview at a Glance
 - 2.1. 7 Major Market Size of Primary Biliary Cholangitis (PBC) in 2017
 - 2.2. 7 Major Market Size of Primary Biliary Cholangitis (PBC) in 2027
3. Disease Background and Overview: Primary Biliary Cholangitis (PBC)
 - 3.1. Introduction
 - 3.2. Causes
 - 3.3. Pathophysiology
 - 3.4. Symptoms
 - 3.5. Risk Factor
 - 3.6. Diagnosis
4. Epidemiology and Patient Population
 - 4.1. Assumptions and Caveats
 - 4.2. 7MM Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)
 - 4.3. Gender specific prevalence of Primary Biliary Cholangitis (PBC)
 - 4.4. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5. Primary Biliary Cholangitis (PBC): Country- Wise Epidemiology

5.1. United States

5.1.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

5.1.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

5.1.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5.2. EU-5

5.2.1. Germany

5.2.1.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

5.2.1.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

5.2.1.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5.2.2. France

5.2.2.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

5.2.2.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

5.2.2.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5.2.3. Italy

5.2.3.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

5.2.3.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

5.2.3.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5.2.4. Spain

5.2.4.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

5.2.4.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

5.2.4.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5.2.5. United Kingdom

5.2.5.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

5.2.5.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

5.2.5.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5.3. Japan

5.3.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

5.3.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

5.3.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

6. Treatment & Medical Practices

6.1. Treatment Algorithm

6.2. Treatment Guidelines

7. Marketed drugs

7.1. Ursodeoxycholic acid: Axcan Pharma

7.1.1. Product Description

7.1.2. Mechanism of action

7.1.3. Regulatory milestones

7.1.4. Other Development Activities

7.1.5. Safety and Efficacy

- 7.1.6. Advantages and Disadvantages
- 7.1.7. Product Profile
- 7.2. Obeticholic acid: Intercept Pharmaceuticals
 - 7.2.1. Product Description
 - 7.2.2. Mechanism of action
 - 7.2.3. Regulatory milestones
 - 7.2.4. Other Development Activities
 - 7.2.5. Safety and Efficacy
 - 7.2.6. Advantages and Disadvantages
 - 7.2.7. Product Profile

To be continued in the report...

- 8. Emerging Therapies
 - 8.1. Key Cross Competition
 - 8.2. Seladelpar: CymaBay Therapeutics
 - 8.2.1. Regulatory Milestones
 - 8.2.2. Clinical Development
 - 8.2.3. Product Profile
 - 8.2.4. Clinical Pipeline Activity
 - 8.2.4.1. Ongoing Trials Information
 - 8.2.4.2. Clinical Trial by Phase
 - 8.3. Etrasimod: Arena Pharmaceuticals
 - 8.3.1. Regulatory Milestones
 - 8.3.2. Clinical Development
 - 8.3.3. Product Profile
 - 8.3.4. Clinical Pipeline Activity
 - 8.3.4.1. Ongoing Trials Information
 - 8.3.4.2. Clinical Trial by Phase
 - 8.4. FFP104: Fast Forward Pharmaceuticals
 - 8.4.1. Regulatory Milestones
 - 8.4.2. Clinical Development
 - 8.4.3. Product Profile
 - 8.4.4. Clinical Pipeline Activity
 - 8.4.4.1. Ongoing Trials Information
 - 8.4.4.2. Clinical Trial by Phase

To be continued in the report...

- 9. Primary Biliary Cholangitis (PBC): Market Size
 - 9.1. Key Findings
 - 9.2. Total 7MM Primary Biliary Cholangitis (PBC) Market Analysis
 - 9.2.1. Overview of Total Primary Biliary Cholangitis (PBC) Market
 - 9.2.2. Market size of Primary Biliary Cholangitis (PBC) by 7MM (2016-2027)

10. 7MM Primary Biliary Cholangitis (PBC): Country-Wise Market Analysis

10.1. United States

10.1.1. Total Market Size of Primary Biliary Cholangitis (PBC)

10.1.2. Market Size of Primary Biliary Cholangitis (PBC) by Therapies

10.2. Germany

10.2.1. Total Market Size of Primary Biliary Cholangitis (PBC)

10.2.2. Market Size of Primary Biliary Cholangitis (PBC) by Therapies

10.3. France

10.3.1. Total Market Size of Primary Biliary Cholangitis (PBC)

10.3.2. Market Size of Primary Biliary Cholangitis (PBC) by Therapies

10.4. United Kingdom

10.4.1. Total Market Size of Primary Biliary Cholangitis (PBC)

10.4.2. Market Size of Primary Biliary Cholangitis (PBC) by Therapies

10.5. Spain

10.5.1. Total Market Size of Primary Biliary Cholangitis (PBC)

10.5.2. Market Size of Primary Biliary Cholangitis (PBC) by Therapies

10.6. Italy

10.6.1. Total Market Size of Primary Biliary Cholangitis (PBC)

10.6.2. Market Size of Primary Biliary Cholangitis (PBC) by Therapies

10.7. Japan

10.7.1. Total Market Size of Primary Biliary Cholangitis (PBC)

10.7.2. Market Size of Primary Biliary Cholangitis (PBC) by Therapies

11. Report Methodology

11.1. Sources Used

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Tables

Table 1 7MM Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

Table 2 7MM Gender specific prevalence of Primary Biliary Cholangitis (PBC) (2016-2027)

Table 3 7MM Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) (2016-2027)

Table 4 Prevalent cases of Primary Biliary Cholangitis (PBC) in the US (2016-2027)

Table 5 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in the US (2016-2027)

Table 6 Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC) in the US (2016-2027)

Table 7 Prevalent cases of Primary Biliary Cholangitis (PBC) in Germany (2016-2027)

Table 8 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Germany (2016-2027)

Table 9 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Germany (2016-2027)

Table 10 Prevalent cases of Primary Biliary Cholangitis (PBC) in France (2016-2027)

Table 11 Gender specific prevalence of Primary Biliary Cholangitis (PBC) disease in France (2016-

2027)

Table 12 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in France (2016-2027)

Table 13 Prevalent cases of Primary Biliary Cholangitis (PBC) in Italy (2016-2027)

Table 14 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Italy (2016-2027)

Table 15 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Italy (2016-2027)

Table 16 Prevalent cases of Primary Biliary Cholangitis (PBC) in Spain (2016-2027)

Table 17 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Spain (2016-2027)

Table 18 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Spain (2016-2027)

Table 19 Prevalent cases of Primary Biliary Cholangitis (PBC) in the UK (2016-2027)

Table 20 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in the UK (2016-2027)

Table 21 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in the UK (2016-2027)

Table 22 Prevalent cases of Primary Biliary Cholangitis (PBC) in Japan (2016-2027)

Table 23 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Japan (2016-2027)

Table 24 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Japan (2016-2027)

Table 25 Seladelpar, Clinical Trials by Recruitment status, 2018

Table 26 Seladelpar, Clinical Trials by Zone, 2018

Table 27 Etrasimod, Clinical Trials by Recruitment status, 2018

Table 28 Etrasimod, Clinical Trials by Zone, 2018

Table 29 FFP104, Clinical Trials by Recruitment status, 2018

Table 30 FFP104, Clinical Trials by Zone, 2018

Table 31 7 Major Market Size in USD, Million (2016-2027)

Table 32 Region wise Market Size in USD, Million (2016-2027)

Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)

Table 34 United States Market Size in USD, Million (2016-2027)

Table 35 United States Market Size by Therapy in USD, Million (2016-2027)

Table 36 Germany Market Size in USD, Million (2016-2027)

Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)

Table 38 France Market Size in USD, Million (2016-2027)

Table 39 France Market Size by Therapy in USD, Million (2016-2027)

Table 40 Italy Market Size in USD, Million (2016-2027)

Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)

Table 42 Spain Market Size in USD, Million (2016-2027)

Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)

Table 44 United Kingdom Market Size in USD, Million (2016-2027)

Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)

Table 46 Japan Market Size in USD, Million (2016-2027)

Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

List of Figures

Figure 1 7MM Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

Figure 2 7MM Gender specific prevalence of Primary Biliary Cholangitis (PBC) (2016-2027)

Figure 3 7MM Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) (2016-2027)

Figure 4 Prevalent cases of Primary Biliary Cholangitis (PBC) in the US (2016-2027)

Figure 5 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in the US (2016-2027)

Figure 6 Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC) in the US (2016-2027)

Figure 7 Prevalent cases of Primary Biliary Cholangitis (PBC) in Germany (2016-2027)

Figure 8 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Germany (2016-2027)

Figure 9 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Germany (2016-2027)

Figure 10 Prevalent cases of Primary Biliary Cholangitis (PBC) in France (2016-2027)

Figure 11 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in France (2016-2027)

Figure 12 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in France (2016-2027)

Figure 13 Prevalent cases of Primary Biliary Cholangitis (PBC) in Italy (2016-2027)

Figure 14 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Italy (2016-2027)

Figure 15 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Italy (2016-2027)

Figure 16 Prevalent cases of Primary Biliary Cholangitis (PBC) in Spain (2016-2027)

Figure 17 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Spain (2016-2027)

Figure 18 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Spain (2016-2027)

Figure 19 Prevalent cases of Primary Biliary Cholangitis (PBC) in the UK (2016-2027)

Figure 20 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in the UK (2016-2027)

Figure 21 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in the UK (2016-2027)

Figure 22 Prevalent cases of Primary Biliary Cholangitis (PBC) in Japan (2016-2027)

Figure 23 Gender specific prevalence of Primary Biliary Cholangitis (PBC) in Japan (2016-2027)

Figure 24 Diagnosed and Treatable cases of Primary Biliary Cholangitis (PBC) in Japan (2016-2027)

Figure 25 Seladelpar, Clinical Trials by Recruitment status, 2018

Figure 26 Seladelpar, Clinical Trials by Zone, 2018

Figure 27 Etrasimod, Clinical Trials by Recruitment status, 2018

Figure 28 Etrasimod, Clinical Trials by Zone, 2018

Figure 29 FFP104, Clinical Trials by Recruitment status, 2018

Figure 30 FFP104, Clinical Trials by Zone, 2018

Figure 31 7 Major Market Size in USD, Million (2016-2027)

Figure 32 Region wise Market Size in USD, Million (2016-2027)

Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)

Figure 34 United States Market Size in USD, Million (2016-2027)

Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)

Figure 36 Germany Market Size in USD, Million (2016-2027)

Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)

Figure 38 France Market Size in USD, Million (2016-2027)

Figure 39 France Market Size by Therapy in USD, Million (2016-2027)

Figure 40 Italy Market Size in USD, Million (2016-2027)

Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)

Figure 42 Spain Market Size in USD, Million (2016-2027)

Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)

Figure 44 United Kingdom Market Size in USD, Million (2016-2027)

Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)

Figure 46 Japan Market Size in USD, Million (2016-2027)

Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but

may not share the publication (or any information contained therein) with any other person or persons outside of the organization.

- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

[What is drug pipeline research?](#)

March 20

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

Source URL: <https://www.drugpipeline.net/delveinsight/primary-biliary-cholangitis-pbc-market-insights-epidemiology-and-market-forecast-2027>

Links

[1] <https://www.drugpipeline.net/region/global>